BioCentury
ARTICLE | Company News

Europe approves Amgen's Aranesp

June 11, 2001 7:00 AM UTC

Europe granted marketing approval to AMGN for its Aranesp modified erythropoietin to treat anemia in patients with chronic renal failure. Aranesp is to be dosed once a week or once every two weeks. AMGN's first generation Epogen recombinant erythropoietin is given three times a week. ...